JF
Judah Frommer Morgan Stanley Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Trevi Therapeutics
TRVI
$854M
| $7.01 | $18 |
157%
upside
| Overweight | 17 days ago |
|
2
Apellis Pharmaceuticals
APLS
$3.55B
| $28.13 | $26 |
8%
downside
| Equal-Weight | 2 months ago |
|
3
Celldex Therapeutics
CLDX
$1.52B
| $22.87 | $43 |
88%
upside
| Overweight | 4 months ago |
|
|
ABVX
4
Abivax
ABVX
$6.65B
| $88.03 | $12 |
86%
downside
| Equal-Weight | 5 months ago |
|
5
Regenxbio
RGNX
$490M
| $9.71 | $24 |
147%
upside
| Overweight | 5 months ago |
|
6
Galapagos
GLPG
$2.2B
| $33.36 | $22 |
34%
downside
| Underweight | 6 months ago |
|
7
4D Molecular Therapeutics
FDMT
$340M
| $7.27 | $6 |
17%
downside
| Underweight | 7 months ago |
|
8
Arcellx
ACLX
$4.03B
| $72.62 | $106 |
46%
upside
| Overweight | 10 months ago |
|
|
BCAX
9
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $12.06 | $35 |
190%
upside
| Overweight | 11 months ago |
|
10
ProKidney
PROK
$304M
| $2.25 | $3 |
33%
upside
| Equal-Weight | 1 year ago |
|
11
Avidity Biosciences
RNA
$6.48B
| $50.36 | $30 |
40%
downside
| Outperform | 2 years ago |
|
12
Stoke Therapeutics
STOK
$1.13B
| $20.68 | $23 |
11%
upside
| Outperform | 2 years ago |
|
13
PTC Therapeutics
PTCT
$4.55B
| $57.26 | $50 |
13%
downside
| Neutral | 2 years ago |
|
14
Sarepta Therapeutics
SRPT
$1.96B
| $18.71 | $141 |
654%
upside
| Neutral | 2 years ago |
|
15
ATAI Life Sciences
ATAI
$980M
| $4.57 | $9 |
97%
upside
| Outperform | 2 years ago |
|
16
NewAmsterdam Pharma
NAMS
$3.04B
| $27 | $22 |
19%
downside
| Outperform | 2 years ago |
|
17
Candel Therapeutics
CADL
$274M
| $5 | $7 |
40%
upside
| Outperform | 2 years ago |
|
18
Fulcrum Therapeutics
FULC
$414M
| $7.66 | $8 |
4%
upside
| Neutral | 2 years ago |
|
19
Inhibrx
INBX
$408M
| $28.18 | $46 |
63%
upside
| Outperform | 2 years ago |
|
20
Esperion Therapeutics
ESPR
$540M
| $2.68 | $7 |
161%
upside
| Neutral | 2 years ago |
|
21
uniQure
QURE
$985M
| $17.95 | $55 |
206%
upside
| Outperform | 2 years ago |
|
22
Insmed
INSM
$30.7B
| $145.10 | $46 |
68%
downside
| Outperform | 2 years ago |
|
23
Performance Food Group
PFGC
$16.5B
| $105.42 | $49 |
54%
downside
| Outperform | 4 years ago |
|
24
Costco
COST
$427B
| $963.48 | $370 |
62%
downside
| Neutral | 4 years ago |
|
25
US Foods
USFD
$17.5B
| $77.91 | $31 |
60%
downside
| Outperform | 5 years ago |
|